BKS Research Kft.
- Address
- lock Available on a paid plan
Cardiovascular Diseases and Metabolic Research
At BKS Research Kft. in Hatvan, Hungary, a major share of the clinical research focuses on cardiovascular disease and nutritional and metabolic disorders. The studies are designed to assess new approaches for reducing heart-related events, improving heart failure care, and supporting better control of conditions linked to obesity, type 2 diabetes, and hypertension.
- Testing new treatments aimed at lowering the risk of cardiovascular events in people with established or high-risk heart disease
- Evaluating therapies for heart failure, including forms with preserved and reduced pumping function
- Studying treatment options for obesity, overweight, and related cardiometabolic conditions
This research area combines prevention and treatment goals, with a strong emphasis on improving outcomes for patients at risk of serious heart and metabolic complications.
Respiratory Tract Diseases
The site also supports studies in respiratory medicine, especially for chronic obstructive pulmonary disease, asthma, and bronchiectasis. These trials are centered on easing breathing problems, reducing flare-ups, and comparing inhaled therapies to find more effective and better-tolerated options.
- Assessing treatments for COPD to improve lung function and reduce exacerbations
- Comparing inhaled therapies for asthma control and airway safety
- Investigating options for bronchiectasis to help lower pulmonary worsening over time
Overall, the respiratory portfolio is aimed at improving symptom control and long-term disease management in common and chronic lung diseases.
Digestive System Diseases and Inflammatory Conditions
Research at this facility includes gastroenterology, with trials in ulcerative colitis that explore how well new treatments can induce remission and relieve intestinal inflammation. The goal is to improve day-to-day disease control for patients living with active bowel disease.
- Evaluating therapies for ulcerative colitis to achieve clinical remission
- Focusing on better control of digestive tract inflammation and related symptoms
- Supporting studies that aim to improve treatment effectiveness in chronic intestinal disease
This area reflects a practical focus on symptom relief, remission, and improved quality of life for people with inflammatory bowel disease.
Nervous System Diseases and Pain-Related Research
The site is involved in studies of diabetic sensorimotor polyneuropathy, a nerve complication associated with diabetes that can cause pain, numbness, and loss of sensation. These trials are intended to assess whether new combined treatments can better ease symptoms and support nerve-related function.
- Investigating symptom relief in diabetic neuropathy
- Comparing treatment strategies for nerve pain and sensory problems
- Exploring improved care for diabetes-related neurological complications
This research area highlights the site’s interest in finding more effective ways to manage chronic neuropathic symptoms linked to metabolic disease.
Skin and Connective Tissue Diseases
Another important field at BKS Research Kft. is the study of chronic venous ulcers, where the focus is on helping stubborn wounds heal and improving local treatment options. These trials are designed to evaluate whether new therapies can support wound closure in patients whose ulcers have not responded well to standard care.
- Testing treatments for non-healing venous leg ulcers
- Assessing wound closure and treatment safety
- Exploring better care for chronic skin and tissue damage
The work in this area is focused on practical healing outcomes and improving options for patients with difficult-to-treat wounds.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 7 therapeutic areas and 15 of 28 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in BKS Research Kft.
lock Showing 1 of 26 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 28 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Beclometasone Dipropionate Anhydrous | 3 | Unknown | 2022-04-22 | 2026-04-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
